Naoki Tarui
Chief Executive Officer, SEEDSUPPLY INC.
Naoki Tarui is listed as Chief Executive Officer, SEEDSUPPLY INC.. Naoki is scheduled to speak at SLAS 2027 International Conference & Exhibition on 1 February 2027.
Compiled from published conference agendas; not yet confirmed by Naoki. Is this you? Claim this profile.
About
Naoki Tarui, PhD, is Founder and CEO of SEEDSUPPLY INC., a Takeda Pharmaceutical spin-out and wholly owned subsidiary of JMDC Inc., based at Shonan iPark. He spent over three decades at Takeda working in early drug discovery, particularly assay development and hit identification. His work included the screening campaign that led to vonoprazan, a marketed potassium-competitive acid blocker, for which he demonstrated competitive binding in gastric microsomes. He received the Pharmaceutical Society of Japan Award for Drug Research and Development in 2016 for his contribution to its discovery. He subsequently led the development of label-free affinity selection mass spectrometry (ASMS) for membrane proteins in their native membranes, without solubilization, and later served as Senior Director of Takeda's Biomolecular Research Laboratories. In 2017, he founded SEEDSUPPLY to address a persistent challenge in drug discovery: despite their importance as therapeutic targets, quantitative bindin